Literature DB >> 15480987

CFTR Cl- channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis.

Stephanie Hirtz1, Tanja Gonska, Hans H Seydewitz, Jörg Thomas, Peter Greiner, Joachim Kuehr, Matthias Brandis, Irmgard Eichler, Herculano Rocha, Ana-Isabel Lopes, Celeste Barreto, Anabela Ramalho, Margarida D Amaral, Karl Kunzelmann, Marcus Mall.   

Abstract

BACKGROUND & AIMS: Cystic fibrosis (CF) is caused by over 1000 mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and presents with a widely variable phenotype. Genotype-phenotype studies identified CFTR mutations that were associated with pancreatic sufficiency (PS). Residual Cl- channel function was shown for selected PS mutations in heterologous cells. However, the functional consequences of most CFTR mutations in native epithelia are not well established.
METHODS: To elucidate the relationships between epithelial CFTR function, CFTR genotype, and patient phenotype, we measured cyclic adenosine monophosphate (cAMP)-mediated Cl- secretion in rectal biopsy specimens from 45 CF patients who had at least 1 non-DeltaF508 mutation carrying a wide spectrum of CFTR mutations. We compared CFTR genotypes and clinical manifestations of CF patients who expressed residual CFTR-mediated Cl- secretion with patients in whom Cl- secretion was absent.
RESULTS: Residual anion secretion was detected in 40% of CF patients, and was associated with later disease onset (P < 0.0001), higher frequency of PS (P < 0.0001), and less severe lung disease (P < 0.05). Clinical outcomes correlated with the magnitude of residual CFTR activity, which was in the range of approximately 12%-54% of controls.
CONCLUSIONS: Specific CFTR mutations confer residual CFTR function to rectal epithelia, which is related closely to a mild disease phenotype. Quantification of rectal CFTR-mediated Cl- secretion may be a sensitive test to predict the prognosis of CF disease and identify CF patients who would benefit from therapeutic strategies that would increase residual CFTR activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15480987     DOI: 10.1053/j.gastro.2004.07.006

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  35 in total

1.  Ulcerative colitis patients in remission have an altered secretory capacity in the proximal colon despite macroscopically normal mucosa.

Authors:  J K Gustafsson; G C Hansson; H Sjövall
Journal:  Neurogastroenterol Motil       Date:  2012-06-24       Impact factor: 3.598

2.  Homozygous CFTR mutation M348K in a boy with respiratory symptoms and failure to thrive. Disease-causing mutation or benign alteration?

Authors:  Julia Hentschel; Gabriele Riesener; Heike Nelle; Manfred Stuhrmann; Anja Schöner; Olaf Sommerburg; Eva Fritzsching; Marcus A Mall; Ferdinand von Eggeling; Jochen G Mainz
Journal:  Eur J Pediatr       Date:  2012-01-25       Impact factor: 3.183

3.  Correlating Cystic Fibrosis Transmembrane Conductance Regulator Function with Clinical Features to Inform Precision Treatment of Cystic Fibrosis.

Authors:  Allison F McCague; Karen S Raraigh; Matthew J Pellicore; Emily F Davis-Marcisak; Taylor A Evans; Sangwoo T Han; Zhongzhou Lu; Anya T Joynt; Neeraj Sharma; Carlo Castellani; Joseph M Collaco; Mary Corey; Michelle H Lewis; Chris M Penland; Johanna M Rommens; Anne L Stephenson; Patrick R Sosnay; Garry R Cutting
Journal:  Am J Respir Crit Care Med       Date:  2019-05-01       Impact factor: 21.405

4.  The {omega}-3 fatty acid eicosapentaenoic acid elicits cAMP generation in colonic epithelial cells via a "store-operated" mechanism.

Authors:  Jessica Roy; Konstantinos Lefkimmiatis; Mary Pat Moyer; Silvana Curci; Aldebaran M Hofer
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-06-24       Impact factor: 4.052

Review 5.  The third dimension: new developments in cell culture models for colorectal research.

Authors:  Joana F S Pereira; Nikhil T Awatade; Cláudia A Loureiro; Paulo Matos; Margarida D Amaral; Peter Jordan
Journal:  Cell Mol Life Sci       Date:  2016-05-04       Impact factor: 9.261

Review 6.  Biomarkers for cystic fibrosis drug development.

Authors:  Marianne S Muhlebach; J P Clancy; Sonya L Heltshe; Assem Ziady; Tom Kelley; Frank Accurso; Joseph Pilewski; Nicole Mayer-Hamblett; Elizabeth Joseloff; Scott D Sagel
Journal:  J Cyst Fibros       Date:  2016-10-27       Impact factor: 5.482

Review 7.  Stem cell-derived organoids to model gastrointestinal facets of cystic fibrosis.

Authors:  Meike Hohwieler; Lukas Perkhofer; Stefan Liebau; Thomas Seufferlein; Martin Müller; Anett Illing; Alexander Kleger
Journal:  United European Gastroenterol J       Date:  2016-09-21       Impact factor: 4.623

8.  Organoids as a personalized medicine tool for ultra-rare mutations in cystic fibrosis: The case of S955P and 1717-2A>G.

Authors:  Iris A L Silva; Tereza Doušová; Sofia Ramalho; Raquel Centeio; Luka A Clarke; Violeta Railean; Hugo M Botelho; Andrea Holubová; Iveta Valášková; Jiunn-Tyng Yeh; Tzyh-Chang Hwang; Carlos M Farinha; Karl Kunzelmann; Margarida D Amaral
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-07-28       Impact factor: 5.187

Review 9.  Ion Channel Modulators in Cystic Fibrosis.

Authors:  Martina Gentzsch; Marcus A Mall
Journal:  Chest       Date:  2018-05-08       Impact factor: 9.410

10.  Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle.

Authors:  Kang-Yang Jih; Tzyh-Chang Hwang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.